Evidence map›Paper›PMID 30906326›Full record

ArticleJournal of probability and statistics2018

A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.

Márcio Augusto Diniz, Sungjin Kim, Mourad Tighiouart

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of probability and statistics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Márcio Augusto DinizBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center 8700 Beverly Blvd, Los Angeles, CA 90048.
Sungjin KimBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center 8700 Beverly Blvd, Los Angeles, CA 90048.
Mourad TighiouartBiostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center 8700 Beverly Blvd, Los Angeles, CA 90048.
Cedars-Sinai Medical Center · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Prostate Cancer Bone Metastasis: Biology and TargetingP01CA098912 · NCI · EMORY UNIVERSITY · PI ZAYZAFOON, MAJD · 2003 to 2019
$24.0M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Design of Cancer Phase I/II Clinical Trials Using Drug Combinations of Cytotoxic and Biologic AgentsR01CA188480 · NCI · CEDARS-SINAI MEDICAL CENTER · PI TIGHIOUART, MOURAD · 2014 to 2018
$1.8M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS P01 CA098912NCI NIH HHS R01 CA188480NCRR NIH HHS UL1 RR033176
6 · The paper itself

Abstract

A Bayesian adaptive design for dose finding of a combination of two drugs in cancer phase I clinical trials that takes into account patients heterogeneity thought to be related to treatment susceptibility is described. The estimation of the maximum tolerated dose (MTD) curves is a function of a baseline covariate using two cytotoxic agents. A logistic model is used to describe the relationship between the doses, baseline covariate, and the probability of dose limiting toxicity (DLT). Trial design proceeds by treating cohorts of two patients simultaneously using escalation with overdose control (EWOC), where at each stage of the trial, the next dose combination corresponds to the

Indexed as

Baseline covariateCancer Phase I trialsContinuous doseDiscrete doseDose limiting toxicityDrug combinationEscalation with overdose controlMaximum tolerated dose

Identifiers

PMID30906326
PMCPMC6428433
OpenAlexW2898913558

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.